

## NEO-EXCEL Trial

Phase III neoadjuvant trial of pre-operative exemestane or letrozole +/- celecoxib in the treatment of ER positive postmenopausal early breast cancer.

**EudraCT number** 2006-000436-27

**Study number** BR3031

**Status** Actively recruiting

**Opened** August 2007

**Expected recruitment duration** 7 Years

A randomised, phase III, bifactorial clinical trial for ER positive postmenopausal early breast cancer to determine whether the addition of a COX 2 inhibitor to a 16 week treatment regimen of pre-operative exemestane or letrozole results in greater clinical response, with acceptable toxicity, than an aromatase inhibitor alone; and to determine whether exemestane provides greater objective clinical response than letrozole in the neoadjuvant setting

If you are a Health Care Professional and would like access to the site for Investigators or would like to be considered for participation in the trial please contact the NEO-EXCEL Trial Office by email [neoexcel@trials.bham.ac.uk](mailto:neoexcel@trials.bham.ac.uk) (<mailto:neoexcel@trials.bham.ac.uk>).

For general enquires about the trial please email [neoexcel@trials.bham.ac.uk](mailto:neoexcel@trials.bham.ac.uk) (<mailto:neoexcel@trials.bham.ac.uk>).

NEO-EXCEL is an NCRN adopted trial.